COVID-19: Vaccines and Therapeutics
Johnson & Johnson said its phase 3 trial data confirms its vaccine’s durability and provided evidence of a second, booster shot’s effectiveness against COVID-19.
The Food and Drug Administration authorized administering the monoclonal antibodies bamlanivimab and etesevimab together to prevent COVID-19 in certain children and adults exposed to SARS-CoV-2 who are not fully vaccinated against COVID-19 and at high-risk for progressing to severe disease.
Pfizer released the first data evaluating a COVID-19 vaccine’s safety and effectiveness for children between the ages of 5 and 11.
The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee by a unanimous vote recommended that the FDA issue an emergency use authorization that would enable COVID-19 vaccine boosters for individuals age 65 and older and those at high risk for severe COVID-19,…
Inspiring nurse joins COVID-19 task force and launches community vaccination team.
As COVID-19 care demands “outstrip resources” at some Idaho hospitals, health care leaders came together to discuss how they are addressing the crisis and reiterate the solution: vaccination.
Saline Health CEO says vaccine strategies must “start with the heart.”
The Centers for Disease Control and Prevention revealed the comparative effectiveness of the three Food and Drug Administration-authorized COVID-19 vaccines, with Moderna’s vaccine deemed most effective at preventing hospitalizations.
The Department of Health and Human Services’ Assistant Secretary for Preparedness and Response announced a major change in the distribution of COVID-19 monoclonal antibody therapies.
The Department of Health and Human Services’ (HHS) Assistant Secretary for Preparedness and Response (ASPR) Sept. 13 announced a major change in the distribution of COVID-19 monoclonal antibody therapies.